Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04870281 · ClinicalTrials.gov registry record
Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System
A clinical trial, sponsored by Biotronik.
- Terminated
- Registry status
- 13
- Enrollment target
NCT04870281 is a clinical trial that was terminated before completion, run by Biotronik. The registered enrollment target is 13 participants.
The verdict
NCT04870281 was terminated before completion, sponsored by Biotronik.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of patient outcomes between AF subtypes.
Interventions
- DEVICE CRT-DX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2021-12-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04870281
The ClinicalTrials.gov registry entry for NCT04870281 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotronik, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CRT-DX is the first listed.
NCT04870281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04870281 about?
NCT04870281 is a clinical study titled "Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System". The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of patient outcomes between AF subtypes.
What is the current status of trial NCT04870281?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2021-05-28. Estimated completion is 2021-12-29.
What interventions are being tested in trial NCT04870281?
The interventions under investigation include: CRT-DX (DEVICE).
Who is sponsoring clinical trial NCT04870281?
This trial is sponsored by Biotronik, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.